Sustainability, affordability, and equity of corporate drug donations: the case of Malarone
- 1 May 2000
- journal article
- Published by Elsevier in The Lancet
- Vol. 355 (9216) , 1718-1720
- https://doi.org/10.1016/s0140-6736(00)02251-0
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Towards an Understanding of the Mechanism of Pyrimethamine-Sulfadoxine Resistance in Plasmodium falciparum : Genotyping of Dihydrofolate Reductase and Dihydropteroate Synthase of Kenyan ParasitesAntimicrobial Agents and Chemotherapy, 2000
- Models to predict the intensity of Plasmodium falciparum transmission: applications to the burden of disease in KenyaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1998
- The "Roll Back Malaria" CampaignScience, 1998
- Malarone-donation programme in AfricaThe Lancet, 1998
- Malarone-donation programmeThe Lancet, 1997
- Malarone-donation programme in AfricaThe Lancet, 1997
- Promising antimalarial combination highlightedThe Lancet, 1996